ArticleDrug design, development and therapy2025
A Novel Letrozole Stair-Step Duration Regimen for Ovulation Induction in Women with Polycystic Ovary Syndrome and Letrozole Resistance.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Letrozole Stair-Step Duration Regimen for Ovulation Induction in Women with Polycystic Ovary Syndrome and Letrozole Resistance.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Letrozole is the first-line treatment for ovulation induction in women with polycystic ovary syndrome (PCOS). However, a subset of patients remains anovulatory despite standard treatment, a condition termed "letrozole resistance". This retrospective cohort study aimed to evaluate the effectiveness and time efficiency of a novel "letrozole stair-step duration regimen", which skips progestin-induced withdrawal bleeding and proceeds directly to an extended letrozole course after anovulatory cycles, compared with a previously established "2-step extended letrozole regimen". Methods: We analyzed 158 women with PCOS and letrozole resistance who underwent ovulation induction at two university-affiliated reproductive centers between March 2018 and September 2024. Participants received either the stair-step duration regimen (n = 62) or the 2-step extended regimen (n = 96). Outcomes compared included follicular development, hormone profiles, ovulation, and pregnancy outcomes. The primary outcome was the ovulation rate. Results: Ovulation rates were comparable between groups [95.16% vs 94.79%]. Clinical pregnancy rates [23.73% (14/59) vs 20.88% (19/91), P = 0.681] and live birth rates [16.95% (11/59) vs 18.68% (17/91), P = 0.824] also showed no significant differences. However, the stair-step group achieved ovulation in a significantly shorter time, with a median of 36 days (interquartile range [IQR] 32-54) versus 47 days (IQR 45-51) in the extended regimen group (P < 0.001). Conclusion: The letrozole stair-step duration regimen is a time-saving and effective ovulation induction protocol for women with PCOS and letrozole resistance, yielding comparable reproductive outcomes in a shorter treatment duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.